Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KPT9274 (PAK4-IN-1) 是一种非竞争性的 PAK4 和 NAMPT 双重抑制剂(IC50= ~120 nM)。它是一种口服生物可利用的小分子。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 679 | 现货 | ||
2 mg | ¥ 980 | 现货 | ||
5 mg | ¥ 1,820 | 现货 | ||
10 mg | ¥ 2,930 | 现货 | ||
25 mg | ¥ 4,860 | 现货 | ||
50 mg | ¥ 6,930 | 现货 | ||
100 mg | ¥ 9,360 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,980 | 现货 |
产品描述 | KPT9274 (PAK4-IN-1) is a non-competitive dual inhibitor of PAK4 and NAMPT(IC50= ~120 nM). It is an orally bioavailable small molecule. |
靶点活性 | NAMPT:~120 nM |
体外活性 | In several human RCC cell lines, KPT-9274 interferences with PAK4 and NAD biosynthetic pathways leading to reduction of G2/M transit as well as induction of apoptosis and decrease in cell invasion and migration. The inhibition of the PAK4 pathway by KPT-9274 attenuates nuclear β-catenin as well as the Wnt/β-catenin targets cyclin D1 and c-Myc. |
体内活性 | In mice, KPT-9274 (200 mg/kg) daily is administered either intravenously or orally with the absence of any signs of toxicity. |
细胞实验 | 786-0, ACHN, Caki-1 and U-2 OS cells are treated with KPT-9274 (1 μM and 5 μM) incubating for 12 hours. |
动物实验 | 786-O (VHL-mut) human RCC xenograft model (nude mice) is treated with KPT-9274 (100 and 200 mg/kg),prepared in 58% Polyvinylpyrrolidone K30 + 21% methyl cellulose + 21% Phospholipon 90 g, by oral gavage. |
别名 | KPT-9274, KPT 9274, PAK4-IN-1 |
分子量 | 610.62 |
分子式 | C35H29F3N4O3 |
CAS No. | 1643913-93-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (90.07 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.6377 mL | 8.1884 mL | 16.3768 mL | 40.942 mL |
5 mM | 0.3275 mL | 1.6377 mL | 3.2754 mL | 8.1884 mL | |
10 mM | 0.1638 mL | 0.8188 mL | 1.6377 mL | 4.0942 mL | |
20 mM | 0.0819 mL | 0.4094 mL | 0.8188 mL | 2.0471 mL | |
50 mM | 0.0328 mL | 0.1638 mL | 0.3275 mL | 0.8188 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KPT9274 1643913-93-2 Cytoskeletal Signaling Metabolism NAMPT PAK KPT-9274 KPT 9274 PAK4-IN-1 Inhibitor inhibitor inhibit